Results 161 to 170 of about 14,385 (213)
Blastic Plasmacytoid Dendritic Cell Neoplasm With del(3)(p14p22): Diagnostic Pitfalls and an Uncommon Cytogenetic Finding in a Vietnamese Patient. [PDF]
J Cutan PatholTran GH, Nguyen TT, Luong KA.
europepmc +1 more source
CD123 Is Consistently Expressed on NPM1-Mutated AML Cells [PDF]
Cancers, 2021 NPM1-mutated (NPM1mut) acute myeloid leukemia (AML) comprises about 30% of newly diagnosed AML in adults. Despite notable advances in the treatment of this frequent AML subtype, about 50% of NPM1mut AML patients treated with conventional treatment die due to disease progression.
Francesca Milano +2 more
exaly +6 more sources
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
International Journal of Molecular Sciences, 2023 In spite of consistent progress at the level of basic research and of clinical treatment, acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. To improve the outcomes of these patients, it is necessary to
Ugo Testa +2 more
exaly +2 more sources
CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies [PDF]
Cancers, 2020 CD123, the α chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, acute lymphoblastic leukemia, hairy
Shilpa Paul +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Expressions of CD30 and CD123 of Mastocytosis in Taiwan
Applied Immunohistochemistry & Molecular Morphology, 2021Mastocytosis is a rare disease with a low incidence in Asia-Pacific populations. CD30 and CD123 may have potential prognostic and therapeutic value, but the results are inconsistent. Because racial disparities may exist, we aim to evaluate the expressions of CD30 and CD123 in a series of mastocytosis cases in Taiwan. Twelve patients with systemic and 7
Ching-Fen, Yang, Chih-Yi, Hsu
openaire +2 more sources
Targeting CD123 in BPDCN: an emerging field
Expert Review of Hematology, 2021Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with historically poor outcomes for patients, often refractory to traditional chemotherapy. Recent research has focused on targeted therapy to improve responses and limit potential toxicity.CD123 (also known as IL-3 Rα) is a cell surface marker and ...
Adam J DiPippo +2 more
openaire +2 more sources
CD123 and its potential clinical application in leukemias
Life Sciences, 2015The α chain of interleukin 3 receptor (IL-3Rα or CD123), together with the common β (βc) subunit, forms a high-affinity IL-3R with biological function. In recent years, emerging research has found that CD123 is highly expressed on the surface of various cells (e.g., leukemia stem cells, LSCs), and it is associated with the initiation and development of
Yechen Xiao
exaly +3 more sources
CD123-targeted therapy in acute myeloid leukemia
Expert Review of Hematology, 2021Acute myeloid leukemia (AML) results from the neoplastic transformation of a hematopoietic stem cell. While therapeutic progress has stagnated for several decades, recent progress in the genomic classification of AML has paved the way for multiple new drug approvals.
Manuel Ricardo Espinoza-Gutarra +3 more
openaire +2 more sources
Clinical Lymphoma Myeloma and Leukemia, 2020
An ideal cell surface target for therapy in leukemia would be: tumor-specific (not expressed on normal cells) or at least enriched on tumor cells, necessary for tumor but not for normal cell survival, internalized efficiently (if the surface-targeted agent is conjugated to chemotherapy or a toxin molecule), and recycled rapidly to the cell surface ...
openaire +2 more sources
An ideal cell surface target for therapy in leukemia would be: tumor-specific (not expressed on normal cells) or at least enriched on tumor cells, necessary for tumor but not for normal cell survival, internalized efficiently (if the surface-targeted agent is conjugated to chemotherapy or a toxin molecule), and recycled rapidly to the cell surface ...
openaire +2 more sources
Hypertrophic lupus erythematosus: the diagnostic utility of CD123 staining [PDF]
Journal of Cutaneous Pathology, 2011 CD123-positive plasmacytoid dendrocytes are prominent in the infiltrate of discoid lupus erythematosus (LE). We hypothesized that these cells would also be present in hypertrophic LE and would aid in the histopathologic distinction from squamous cell carcinoma (SCC) and hypertrophic actinic keratosis (AK).
Jennifer M McNiff, Christine J. Ko
exaly +3 more sources